How to Vet a Compounding Pharmacy for GLP-1 Medications
Not all compounding pharmacies are equal. Here's how to evaluate sourcing, quality controls, and regulatory compliance before starting a compounded GLP-1 program.
Browse all clinician profiles in our reviewer directory.
Freshness status: Fresh (49 days since review)
Clinical change log
Substantive medical-content updates are tracked here for transparency. See our methodology and disclosures.
What changed:Updated clinical guidance language, risk/safety framing, and care-escalation instructions to align with current evidence standards.
Source impact:Primary references were reviewed and retained/updated where needed; claim-to-source traceability preserved.
Search Learn Guides
503A vs 503B: Understanding the Two Types
The FDA regulates compounding pharmacies under two distinct sections of the FD&C Act, and the difference matters significantly for patient safety. 503A pharmacies are traditional compounding pharmacies that prepare medications in response to individual patient prescriptions. They are regulated primarily by state pharmacy boards and are not required to follow current Good Manufacturing Practice (cGMP) standards. Quality can vary significantly between 503A pharmacies.[1] 503B outsourcing facilities are a newer category created by the Drug Quality and Security Act (DQSA) of 2013. These facilities must comply with cGMP standards, undergo FDA inspections, and report adverse events. They can produce medications in larger batches without individual prescriptions, which is how they supply telehealth GLP-1 programs.[2] For GLP-1 therapy, we strongly prefer providers that source from 503B-certified facilities. The cGMP requirement means the pharmacy must maintain validated manufacturing processes, environmental monitoring, potency testing, and sterility assurance — none of which are mandatory for 503A operations.What to Look For: cGMP Audit Documentation
A cGMP-compliant pharmacy should be able to provide documentation demonstrating their quality controls. When evaluating a provider, ask about or look for:- Current FDA registration as a 503B outsourcing facility (verifiable on the FDA website)
- Third-party audit reports from accredited organizations like NABP or state board auditors
- Certificate of Analysis (CoA) for each batch of medication, including potency testing results
- Sterility testing documentation confirming the absence of microbial contamination
- Environmental monitoring records showing cleanroom compliance
Red Flags That Should Stop You
Certain warning signs indicate a compounding pharmacy or telehealth provider may not meet acceptable quality standards:- No 503B registration: If the pharmacy is not registered as a 503B outsourcing facility, it is not subject to cGMP requirements or FDA oversight
- Refusal to provide CoA: A Certificate of Analysis for your specific batch should be available. If the provider cannot produce it, the medication may not have been properly tested
- Pricing too good to be true: Compounded semaglutide below $100/month often means the pharmacy is cutting corners on API sourcing or quality testing
- No adverse-event reporting: 503B facilities are required to report adverse events to the FDA. Ask how the provider tracks and reports side effects
- Opaque sourcing: The provider should be able to tell you the source of their API (active pharmaceutical ingredient) and whether it is sourced from FDA-registered suppliers
- No named pharmacist: Every compounding pharmacy must have a licensed pharmacist-in-charge. If the provider cannot identify theirs, that is a compliance issue
Step-by-Step Verification Process
Here is a practical checklist for verifying a compounding pharmacy before starting treatment: Step 1: Confirm the pharmacy is registered with the FDA as a 503B outsourcing facility. Search the FDA's 503B registration database. Step 2: Request a Certificate of Analysis for the medication batch you will receive. Verify that potency testing shows the medication is within 90-110% of the labeled strength. Step 3: Ask the provider about their API sourcing. Reputable 503B facilities use FDA-registered API suppliers and can provide chain-of-custody documentation. Step 4: Check for state pharmacy board licensure in the state where the pharmacy operates and where you reside. Step 5: Review the provider's adverse-event monitoring process. They should have a system for tracking and reporting side effects to both the FDA and the prescribing physician. Step 6: Verify the provider's telehealth prescribers are licensed in your state and have relevant credentials (MD, DO, NP, or PA with obesity medicine training).[5]Compare Providers Next
Compare options side by side on our GLP-1 provider scorecard, then review coverage workflow details on insurance support comparison. For provider-specific details, read our Alan Meds review.
Payer-specific shortcuts: Aetna, BCBS, Cigna, and UnitedHealthcare.
Semaglutide pricing shortcuts: semaglutide cost, semaglutide cost per month, semaglutide injection cost, and compounded semaglutide cost.
Popular state-specific comparisons: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida .
References
- [1]U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act — Pharmacy Compounding. FDA.gov
- [2]U.S. Food and Drug Administration. Section 503B Outsourcing Facilities — Drug Quality and Security Act (DQSA) of 2013. FDA.gov
- [3]National Association of Boards of Pharmacy (NABP). cGMP Compliance Standards for 503B Outsourcing Facilities. Updated 2025. NABP
- [4]U.S. Food and Drug Administration. FDA Warning Letters to Compounding Pharmacies — GLP-1 Products. 2024-2025. FDA Warning Letters
- [5]U.S. Food and Drug Administration. 503B Outsourcing Facility Registration Database. Updated 2025. FDA 503B Registry
Claim-to-Source Traceability
Reviewer attribution: Anika Reyes, MD
Frequently Asked Questions
Is compounded GLP-1 medication safe?
Compounded GLP-1 medications from 503B-certified outsourcing facilities that follow cGMP standards are generally considered safe. These facilities undergo FDA inspection and must meet the same manufacturing quality standards as pharmaceutical companies. However, quality can vary significantly between providers, so it is essential to verify the pharmacy's credentials and request batch-specific testing documentation.
How do I know if my provider uses a 503B pharmacy?
Ask your provider directly which pharmacy they use and whether it is registered as a 503B outsourcing facility. You can verify this by searching the FDA's 503B registration database. Reputable providers will share this information proactively. If they are evasive or cannot provide a clear answer, consider choosing a different provider.
What is a Certificate of Analysis (CoA)?
A Certificate of Analysis is a laboratory report that tests a specific batch of medication for identity, potency, purity, and sterility. For compounded GLP-1 medications, the CoA should confirm that the active ingredient concentration is within 90-110% of the labeled dose. Reputable 503B facilities provide CoAs for every batch they produce.